Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com
Latest Financials

Filings:

CategoryDateSearch FilingsInstitutional HoldersbetaEarnings TranscriptsbetaGlobal Search

SEC Edgar

Attovia Therapeutics, Inc.

NotesSupport
aboutterms

Institutional HoldersBeta

Who holds a company, from every 13F filed for the quarter, one row per filer exactly as filed, against the latest share count the company reported.

Attovia Therapeutics, Inc.

CIK 0002058707ATTO· quarter ending 2026-06-30
Shares outstanding
45,651,262
as of 2026-08-31 · 10-Q cover page, filed 2026-09-02
Held by 13F filers
0
share count unavailable
Holders
0
+0 vs 2026-03-31 · 0 new, 0 exited
Value
$0
shares +— vs prior quarter

Share classes (cover page of the 10-Q filed 2026-09-02, as of 2026-08-31)

ClassListedShares outstandingHeld by 13F filers% of classHoldersCUSIP
Common stockATTO · NASDAQ45,651,262——

Each class is compared with its own share count; classes are not added together. A class that is not exchange-listed cannot be held by 13F filers.

Securities (CUSIPs held in 13F this quarter)

tick to combine
CountCUSIPClass (as filers write it)HoldersShares heldClass shares% of classValueOptionsMapped via

Totals combine the ticked CUSIPs and update as you tick: common-stock classes by default; preferreds, notes, warrants and depositary shares are listed but not counted. "holders →" shows a single CUSIP on its own. Bonds are held as a principal amount, not shares. Options positions are never counted as holdings. 1 further CUSIPs map to this company (mostly bonds) but no 13F filer held them this quarter.

Top holders (0 of 0 · )

change vs 2026-03-31

No 13F holders for the selected CUSIPs this quarter.

Large holders from 13D/13G (latest per reporting person, last 2 years)

Filed when a holder crosses 5% or changes materially, so often more current than the quarter-end 13F. Percentages are the filer's own, against the share count they used.

Reporting personFormFiledEventShares% of class
David KroinSCHEDULE 13G2026-08-122026-08-053,207,1387.45%
Deep Track Biotechnology Master Fund, Ltd.SCHEDULE 13G2026-08-122026-08-053,207,1387.45%
Deep Track Capital, LPSCHEDULE 13G2026-08-122026-08-053,207,1387.45%
FHMLSP, L.L.C.SCHEDULE 13D2026-08-112026-08-06760,3271.7%
FHMLSP, L.P.SCHEDULE 13D2026-08-112026-08-06760,3271.7%
FHMLS XII, L.L.C.SCHEDULE 13D2026-08-112026-08-0654,1630.1%
FHMLS XII, L.P.SCHEDULE 13D2026-08-112026-08-0654,1630.1%
FHMLS XI, L.L.C.SCHEDULE 13D2026-08-112026-08-066,154,21313.5%
FHMLS XI, L.P.SCHEDULE 13D2026-08-112026-08-066,154,21313.5%
Frazier Life Sciences Public Fund, L.P.SCHEDULE 13D2026-08-112026-08-06760,3271.7%
Frazier Life Sciences XII, L.P.SCHEDULE 13D2026-08-112026-08-0654,1630.1%
Frazier Life Sciences XI, L.P.SCHEDULE 13D2026-08-112026-08-066,154,21313.5%

Source: SEC Form 13F-HR information tables for the quarter ending 2026-06-30 (filed within 45 days of quarter end; amendments applied; values normalised to dollars), the share count from the company's latest 10-K/10-Q XBRL cover page, and Schedule 13D/13G filings. Each row is a legal 13F filer as filed — related entities (e.g. Vanguard's advisers) are not merged. Retail brokerage accounts are not reported on 13F, so the remainder is mostly retail and insiders.